Oncothyreon Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ONTY 1.69 -0.04 (-2.31%)
price chart
Oncothyreon Inc (USA) (ONTY): Oncothyreon Offers Income To Those Accepting ...
Oncothyreon Inc. (NASDAQ:ONTY) is a biotechnology corporation that dedicates its available resources to treatments for cancer.
Related articles »  
Best Biotech Stocks To Buy Now [Neuralstem, Inc., Oncothyreon Inc (USA ...
In fact, Tremblay believes that strong growth in prescription drug sales, growth in FDA drug approvals, increasing orphan drug development, and an aging U.S. population are all reasons to invest in biotech stocks now. Now, penny stock investing is ...
Why Biotech Stocks Jumped? - BioCryst Pharmaceuticals, Inc. (BCRX ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Oncothyreon Inc (USA) (NASDAQ:ONTY) following small-cap stocks higher. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) extended gains as ...
Related articles »  
Puma Biotechnology Inc (NYSE:PBYI) Nearly Quadruples, Lifting Cancer ...
... at a fixed rate in the low- to mid- teens. Among other cancer-related stocks, Oncothyreon Inc (USA) (NASDAQ:ONTY), Array Biopharma Inc (NASDAQ:ARRY) and DARA Biosciences Inc (NASDAQ:DARA) each gained more than 15% in sympathy with PBYI.
Why Oncotheryeon, Inc., OncoMed Pharmaceuticals, Inc., and Array BioPharma ...  Motley Fool
Related articles »  
How Has The Market Reacted To Puma Biotechnology's Meteoric Rise ...
Oncothyreon Inc (USA)(NASDAQ:ONTY) gained $0.49 to close at $3.29, a 17.5% increase in value from the closing price recorded on July 22nd, 2014. Notably, the stock traded for as high as $3.60, just $0.48 below its 52 week low of $4.08. Like Puma ...
Closing Bell Reports: Towerstream Corporation (TWER), Oncothyreon Inc ...
Oncothyreon Inc (ONTY)'S monthly performance stands at -16.08% and Oncothyreon Inc (ONTY) is considered a possible seller for the upcoming trading day.
Oncothyreon Inc. (ONTY) EMR 63325-009 Study Misses Primary Endpoint
Merck KGaA (NYSE: MRK), Darmstadt, Germany, has informed Oncothyreon Inc. (Nasdaq: ONTY) that a randomized Phase 1/2 study, EMR 63325-009, of tecemotide compared to placebo in Japanese patients with Stage III non-small cell lung cancer did not ...
Oncothyreon cancer drug test in Japan shows 'no treatment effect,' ...  Puget Sound Business Journal (Seattle) (blog)
Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study - Analyst Blog  NASDAQ
Related articles »  
Sharp Movers Following News: NII Holdings Inc (NASDAQ:NIHD), Vimicro ...
Oncothyreon Inc (USA) (NASDAQ:ONTY) jumped 7.50% after it declared the pricing of previously announced concurrent but separate underwritten offerings of 10,000,000 shares of its Common Stock at a price to the public of $2.00 per share, for expected ...
Related articles »  
Top Stories: Procter & Gamble Co (NYSE:PG), Oncothyreon Inc (NASDAQ:ONTY ...
Buffett to Trade Procter & Gamble Co (NYSE:PG) Stock to Buy Duracell, Structure of Deal Minimizes Tax Hit, Allows Procter to Shed Non-Core Business.
Shareholder Update: Xplore Technologies (XPLR), Oncothyreon (ONTY), Waters ...
In the eyes of analysts at H.C. Wainwright, Oncothyreon Inc (USA) (NASDAQ:ONTY) is a stock worth buying now. The analysts initiated the stock with a �Buy� recommendation and issued $4 target price on it.
Oncothyreon Now Covered by HC Wainright (ONTY)  WKRB News
H.C. Wainwright Starts Oncothyreon (ONTY) at Buy  StreetInsider.com (subscription)
Related articles »